HK Stock Market Move | HBM HOLDINGS-B (02142) surged over 4% in early trading as the Phase II trial of the long-acting TSLP antibody for asthma was successful, and the Phase III clinical trial has now started.
HuaBoh Pharmaceuticals-B (02142) surged more than 4% in the morning session. As of the time of writing, it has increased by 4.67%, priced at HKD 15.23, with a trading volume of HKD 59.8062 million.
HBM HOLDINGS-B (02142) surged over 4% in early trading. As of the time of writing, it rose by 4.67% to HKD 15.23, with a trading volume of HKD 59.8062 million.
In news, on September 8, HeBo Medicine and Kelun-Botai announced that their partner Windward Bio has released positive interim results from the Phase II portion of the POLARIS-1 clinical study. This study is evaluating the efficacy of the ultra-long-acting TSLP dual antibody HBM9378/WIN378 administered biannually for the treatment of asthma. Furthermore, Windward Bio plans to initiate a second Phase III clinical study, POLARIS-2, in the first half of 2027.
Notably, HeBo Medicine has officially been included in the Stock Connect lists for the Hong Kong-Shanghai and Hong Kong-Shenzhen programs since September 7, allowing eligible investors in mainland China to directly invest in the company's shares through these programs. The company's board stated that this inclusion in the Hong Kong Stock Connect will bring in a broader investor base and further enhance the liquidity of its shares.
Related Articles
Yuanyu Securities: The expansion of industrial gas volume combined with shareholder synergy leads to simultaneous improvements in gross margin and debt quality, assigning a "Buy" rating to BINHAI INV (02886).
HK Stock Market Move | GLOBAL NEW MAT (06616) rose nearly 4% in the morning, with the German business segment performing impressively in the first half of the year, and the effects of mergers and integration gradually becoming apparent.
HK Stock Market Move | AXERA (00600) rose over 10% as the company officially entered the Hong Kong Stock Connect and recently launched the M9 series of high-end intelligent driving chips.
Yuanyu Securities: The expansion of industrial gas volume combined with shareholder synergy leads to simultaneous improvements in gross margin and debt quality, assigning a "Buy" rating to BINHAI INV (02886).
HK Stock Market Move | GLOBAL NEW MAT (06616) rose nearly 4% in the morning, with the German business segment performing impressively in the first half of the year, and the effects of mergers and integration gradually becoming apparent.
HK Stock Market Move | AXERA (00600) rose over 10% as the company officially entered the Hong Kong Stock Connect and recently launched the M9 series of high-end intelligent driving chips.
RECOMMEND
